LDC exits £178m global drug research group

MID-market private equity firm LDC’s Manchester office has completed the exit of Lancashire-based Synexus, a global research site group which provides patient recruitment and treatment services in support of drug research for clinical trials, in a deal which values the business at £178m.

Synexus has been acquired by Jaguar Holding Company Luxembourg SARL and the transaction generates a 2.3x money multiple for LDC.

Chorley-headquartered Synexus is one of the only global patient enrolment and investigato... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...

Close